Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.90 |
| ▸ | NPC1 | O15118 | 7/20 | 0.90 |
| ▸ | MEN1 | O00255 | 7/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.90 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | HPGD | P15428 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911599 | 0.95 | RAB9A (0.95) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4284108 | 0.95 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4280110 | 0.94 | RAB9A (0.80) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4280117 | 0.94 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4291514 | 0.94 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4287780 | 0.89 | RAB9A (0.77) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15099496 | 0.87 | KMT2A (0.70) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4285669 | 0.87 | RAB9A (0.69) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9911643 | 0.81 | RAB9A (0.70) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4279011 | 0.81 | RAB9A (0.67) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340837-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-120131648-A | HIV-1 latent infection activator, medicine and application | 上海市重大传染病和生物安全研究院 | 2025-06-13 | — | — | CN | claimed |
| CN-120082502-A | Method for differentiating pluripotent stem cells into insulin-secreting cells | 广西中医药大学附属瑞康医院（广西中西医结合医院） | 2025-06-03 | — | — | CN | claimed |
| CN-119909067-A | Small molecular compound combination and application thereof in glioma treatment | 暨南大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119752767-A | Method for inducing and differentiating human umbilical cord mesenchymal stem cells into islet microsphere organs and application | 辽宁医学诊疗科技研发中心有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119432708-A | In vitro induction method of gastric organoids and application thereof | 广州国家实验室 | 2025-02-14 | — | — | CN | claimed |
| EP-4504916-A1 | CELLS | University of Geneva (CH) | 2025-02-12 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| EP-4440585-A1 | METHOD OF GENERATING FUNCTIONAL ISLETS FROM PLURIPOTENT STEM CELLS | Hangzhou Reprogenix Bioscience, Inc. (CN) | 2024-10-09 | — | — | EP | claimed |
| US-20220362254-A1 | METHODS FOR REPROGRAMMING CANCER CELLS | UNIV JEFFERSON (US) | 2022-11-17 | — | — | US | claimed |
| WO-2022204377-A1 | NOVEL CHEMICAL COMBINATIONS AND METHODS OF USE THEREOF, TOWARDS DIFFERENTIATION OF HUMAN PROGENITOR CELLS INTO FUNCTIONAL β CELLS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022077549-A1 | COMPOSITION AND METHOD FOR TRANSDIFFERENTIATING NON-NEURONAL CELLS INTO NEURONS | 中国科学院动物研究所 | 2022-04-21 | — | — | WO | claimed |
| US-20210363491-A1 | PRODUCTION OF INSULIN PRODUCING CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-25 | — | — | US | claimed |
| US-11021687-B2 | Production of differentiated enteroendocrine cells and insulin producing cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-06-01 | — | — | US | claimed |
| US-10857185-B2 | Compositions and methods for reprogramming non-neuronal cells into neuron-like cells | Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd. (CN) | 2020-12-08 | — | — | US | claimed |
| US-20200277567-A1 | METHODS FOR CHEMICALLY INDUCED LINEAGE REPROGRAMMING | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2020-09-03 | — | — | US | claimed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20180193386-A1 | Compositions and Methods For Reprograming Non-Neuronal Cells Into Neuron-Like Cells | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2018-07-12 | — | — | US | claimed |
| US-20170349884-A1 | Production of Differentiated Enteroendocrine Cells and Insulin Producing Cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | RAB9A 334/4885NPC1 1167/4885MEN1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.